Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation

Cancer

Volumn 107, Issue 11, 2006, Pages 2589-2596

  Krishnan, Sunil ^a   Rana, Vishal ^a   Janjan, Nora A ^a   Abbruzzese, James L ^a   Gould, Morris S ^a   Das, Prajnan ^a   Delclos, Marc E ^a   Palla, Shana ^a   Guha, Sushovan ^a   Varadhachary, Gauri ^a   Evans, Douglas B ^a   Wolff, Robert A ^a   Crane, Christopher H ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Chemoradiation; Locally advanced; Pancreatic cancer; Prognostic factors; Survival

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; DOXORUBICIN; FLUOROPYRIMIDINE; FLUOROURACIL; GEMCITABINE; HEMOGLOBIN; LOMUSTINE; MITOMYCIN; STREPTOZOCIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMORADIATION THERAPY; DISEASE FREE SURVIVAL; DUODENUM ULCER; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; NAUSEA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RETROSPECTIVE STUDY; STOMACH ULCER; UNITED STATES; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREATIC NEOPLASMS;

EID: 33751570321     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22328     Document Type: Article

References (35)

1. Rosewicz S, Wiedenmann R. Pancreatic carcinoma. Lancet. 1997;349:485-489.
2. Jemal A. Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
3. Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg. 1999;189:1-7.
4. Maheshwari V, Moser AJ. Current management of locally advanced pancreatic cancer. Nat Clin Pract Gastroenterol Hepatol. 2005;2:356-364.
5. Moertel CG, Frytak S, Hahn KG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer. 1981;48:1705-1710.
6. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone.Gastrointestinal Tumor Study Group. J Natl Cancer Inst. 1983;80:751-755.
7. Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil - an Eastern Cooperative Oncology Group study. J Clin Oncol. 1985;3:373-378.
8. Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. The Gastrointestinal Tumor Study Group. J Clin Oncol. 1986;4:1794-1798.
9. Oliani C, Padovani M, Manno P, et al. Gemcitabine and continuous infusion of 5-fluorouracil in locally advanced and metastatic pancreatic cancer: a phase I-II study. Anticancer Res. 2004;24:2107-2112.
10. Ferrari V, Valcamonico F, Amoroso V, et al. Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial. Cancer Chemother Pharmacol. 2006;57:185-190.
11. Wang X, Ni Q, Jin M, et al. Gemcitabine or gemcitabine plus cisplatin for in 42 patients with locally advanced or metastatic pancreatic cancer. Zhonghua Zhong Liu Za Zhi. 2002;24:404-407.
12. Okusaka T, Ito Y, Ueno H, et al. Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer. Br J Cancer. 2004;91:673-677.
13. Wolff RA, Evans DB, Gravel DM, et al. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res. 2001;7:2246-2253.
14. Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol. 1991;9:491-498.
15. Ikeda M, Okada S, Tokuuye K, Ueno H, Okusaka T. Prognostic-factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy. Cancer. 2001;91:490-495.
16. Sezgin C, Karabulut B, Uslu R, et al. Gemeitabine treatment in patients with inoperable locally advanced/metastatic pancreatic cancer and prognostic factors. Scand J Gastroenterol. 2005;40:1486-1492.
17. Katz A, Hanlon A, Lanciano R, Hoffman I, Coia L. Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy. Int J Radiat Oncol Biol Phys. 1998;41:393-396.
18. Crane CH, Abbruzzese JL, Evans DB, et al. Is the therapeutic-index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys. 2002;52:1293-1302.
19. Tian F, Appert HE, Myles J, et al. Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma. Ann Surg. 1992;215:350-355.
20. Ishii H, Okada S, Nose H, Yoshimori M, Aoki K, Okusaka T. Prognostic factors in patients with advanced pancreatic cancer treated with systemic chemotherapy. Pancreas. 1996;12:267-271.
21. Ishii H, Okada S, Sato T, et al. CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer. Hepatogastroenterology. 1997;44:279-283.
22. Kaplan BL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;63:457-481.
23. Cox DR. Regression models and life tables [with discussion]. J R Stat Soc Ser B. 1972;34:187-220.
24. Peto R, Peto J. Asymptotically efficient rank invariant procedures (with discussion). J Royal Stat Soc. 1972; Series A 135:185.
25. Ueno H, Okada S, Okusaka T, Ikeda M. Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology. 2000;59:296-301.
26. Terwee CB, Nieveen Van Dijkum KJ, Gouma DJ, et al. Pooling of prognostic studies in cancer of the pancreatic head and periampullary region: the Triple-P study.Triple-P study group. Eur J Surg. 2000;166:706-712.
27. Engelken FJ, Bettschart V, Rahman MQ, Parks RW, Garden OJ. Prognostic factors in the palliation of pancreatic cancer. Eur J Surg Oncol. 2003;29:368-373.
28. Laws ER, Parney IF, Huang W, et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg. 2003;99:467-473.
29. Jeremic B, Milicic B, Dagovic A, Aleksandrovic J, Nikolic N. Pretreatment clinical prognostic factors in patients with stage IV non-small cell lung cancer (NSCLC) treated with chemotherapy. J Cancer Res Clin Oncol. 2003;129:114-122.
30. Kepka L, Cieslak E, Bujko K, Fijuth I, Wierzchowski M. Results of the whole-brain radiotherapy for patients with brain metastases from lung cancer: the RTOG RPA intraclasses analysis. Acta Oncol. 2005;44:389-398.
31. Dunst J, Kuhnt T, Strauss HG, et al. Anemia in cervical cancers: impact on survival, patterns of relapse, and association with hypoxia and angiogenesis. Int J Radiat Oncol Biol Phys. 2003;56:778-787.
32. Kandemir EG, Mayadagli A, Turken O, Yaylaci M, Ozturk A. Pre-treatment haemoglobin concentration is a prognostic factor in patients with early-stage breast cancer. J Int Med Res. 2005;33:319-328.
33. van de Pol SM, Doornaert PA, de Bree R, Leemans CR, Slotman BJ, Langendijk JA. The significance of anemia in squamous cell head and neck cancer treated with surgery and postoperative radiotherapy. Oral Oncol. 2006;42:131-138.
34. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003;362:1255-1260.
35. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol. 2003;4:459-460.